首页> 外文期刊>BMJ Open >The efficacy and safety of complete pericardial drainage by means of intrapericardial fibrinolysis for the prevention of complications of pericardial effusion: a systematic review protocol
【24h】

The efficacy and safety of complete pericardial drainage by means of intrapericardial fibrinolysis for the prevention of complications of pericardial effusion: a systematic review protocol

机译:通过心包内纤溶治疗完全心包引流预防心包积液并发症的有效性和安全性:系统评价方案

获取原文
           

摘要

Introduction Intrapericardial fibrinolysis has been proposed as a means of preventing complications of pericardial effusion such as cardiac tamponade, persistent and recurrent pericardial effusion, and pericardial constriction. There is a need to understand the efficacy and safety of this procedure because it shows promise. Methods and analysis We aim to assess the effects of intrapericardial fibrinolysis in the treatment of pericardial effusion. We will search PubMed, the Cochrane Library, African Journals online, Cumulative Index to Nursing and Allied Health Literature, Trip database, Clinical trials.gov and the WHO International Clinical Trials Registry Platform for studies that evaluate the efficacy and/or safety of complete pericardial fluid drainage by intrapericardial fibrinolysis irrespective of study design, geographical location, language, age of participants, aetiology of pericarditis or types of fibrinolytics. Two authors will do the search independently, screen the search outputs for potentially eligible studies and assess whether the studies meet the inclusion criteria. Discrepancies between the two authors will be resolved through discussion and arbitration by a third author. Data from the selected studies shall be extracted using a standardised data collection form which will be piloted before use. The methodological quality of studies will be assessed using the Cochrane Collaboration's tools for assessing risk of bias for experimental studies and non-randomised studies, respectively. The primary meta-analysis will use random effects models due to expected interstudy heterogeneity. Dichotomous data will be analysed using relative risk and continuous with data mean differences, both with 95% CIs. Ethics and dissemination Approval by an ethics committee is not required for this study as it is a protocol for a systematic review of published studies. The results will be disseminated through a conference presentation and peer-reviewed publication. Review registration number PROSPERO, CRD42014015238.
机译:引言心包内纤溶已被提议作为一种预防心包积液并发症的方法,例如心包填塞,持续性和反复性心包积液以及心包收缩。有必要了解此程序的有效性和安全性,因为它显示出了希望。方法和分析我们旨在评估心包内纤溶治疗心包积液的效果。我们将搜索PubMed,Cochrane图书馆,在线非洲期刊,护理和相关健康文献累积索引,Trip数据库,Clinical trials.gov和WHO国际临床试验注册平台,以评估评估完整心包膜的疗效和/或安全性的研究。不论研究设计,地理位置,语言,受试者年龄,心包炎的病因或纤溶酶的类型如何,均通过心包内纤溶作用引流。两位作者将独立进行搜索,筛选可能符合条件的研究的搜索结果,并评估研究是否符合纳入标准。两位作者之间的差异将通过第三位作者的讨论和仲裁来解决。所选研究的数据应使用标准化数据收集表提取,并将在使用前进行试行。研究的方法学质量将使用Cochrane协作组织的工具分别评估实验研究和非随机研究的偏倚风险进行评估。由于预期的研​​究间异质性,主要的荟萃分析将使用随机效应模型。将使用相对风险来分析二分数据,并使用数据均值连续性进行连续分析,二者均具有95%的置信区间。伦理与传播这项研究不需要伦理委员会的批准,因为它是对已发表研究进行系统审查的协议。结果将通过会议介绍和同行评审的出版物进行传播。查看注册号PROSPERO,CRD42014015238。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号